JP2020514254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514254A5 JP2020514254A5 JP2019532079A JP2019532079A JP2020514254A5 JP 2020514254 A5 JP2020514254 A5 JP 2020514254A5 JP 2019532079 A JP2019532079 A JP 2019532079A JP 2019532079 A JP2019532079 A JP 2019532079A JP 2020514254 A5 JP2020514254 A5 JP 2020514254A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- independently
- compound
- ras protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **C(C=C*)=CC(NC1OC1C(C=[N+])=C(*)Nc1ccc(*)cc1)=* Chemical compound **C(C=C*)=CC(NC1OC1C(C=[N+])=C(*)Nc1ccc(*)cc1)=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434971P | 2016-12-15 | 2016-12-15 | |
| US62/434,971 | 2016-12-15 | ||
| PCT/US2017/066839 WO2018112420A1 (en) | 2016-12-15 | 2017-12-15 | Compositions and methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514254A JP2020514254A (ja) | 2020-05-21 |
| JP2020514254A5 true JP2020514254A5 (https=) | 2021-06-17 |
| JP7191828B2 JP7191828B2 (ja) | 2022-12-19 |
Family
ID=62559666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532079A Active JP7191828B2 (ja) | 2016-12-15 | 2017-12-15 | がん治療のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11136297B2 (https=) |
| EP (1) | EP3555077B1 (https=) |
| JP (1) | JP7191828B2 (https=) |
| KR (1) | KR20190095355A (https=) |
| CN (1) | CN110291084A (https=) |
| AU (1) | AU2017378487B2 (https=) |
| BR (1) | BR112019012263A2 (https=) |
| CA (1) | CA3047125A1 (https=) |
| IL (1) | IL267247B (https=) |
| MX (1) | MX392368B (https=) |
| RU (1) | RU2019121922A (https=) |
| WO (1) | WO2018112420A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| KR20190095355A (ko) * | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| CN114681600A (zh) * | 2018-10-19 | 2022-07-01 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| WO2020146779A1 (en) * | 2019-01-11 | 2020-07-16 | The Regents Of The University Of California | mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN110825862B (zh) * | 2019-11-06 | 2022-12-06 | 北京诺道认知医学科技有限公司 | 基于药学知识图谱的智能问答方法及装置 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US20230242586A1 (en) * | 2020-04-23 | 2023-08-03 | The Regents Of The University Of California | Ras inhibitors and uses thereof |
| WO2021222333A1 (en) * | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| EP4351615A4 (en) * | 2021-06-11 | 2026-01-28 | Rnaimmune Inc | Multiplexed tp53 and pan-ras mrna cancer vaccines |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114044754A (zh) * | 2021-11-23 | 2022-02-15 | 贵州大学 | 一类5-三氟甲基-4-吡唑衍生物的制备方法及其在抑制肿瘤细胞上的应用 |
| CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN120659773A (zh) | 2022-11-09 | 2025-09-16 | 锐新医药公司 | 化合物、复合物以及其制备方法和用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| KR20260027943A (ko) * | 2023-05-26 | 2026-03-03 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US5242794A (en) | 1984-12-13 | 1993-09-07 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6051380A (en) | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
| US6017696A (en) | 1993-11-01 | 2000-01-25 | Nanogen, Inc. | Methods for electronic stringency control for molecular biological analysis and diagnostics |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6068818A (en) | 1993-11-01 | 2000-05-30 | Nanogen, Inc. | Multicomponent devices for molecular biological analysis and diagnostics |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
| US5777324A (en) | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
| US5919626A (en) | 1997-06-06 | 1999-07-06 | Orchid Bio Computer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
| EP1090293B2 (en) | 1998-06-24 | 2019-01-23 | Illumina, Inc. | Decoding of array sensors with microspheres |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| DK1218542T3 (da) | 1999-09-13 | 2004-08-02 | Nugen Technologies Inc | Fremgangsmåder og sammensætninger til lineær isotermisk amplifikation af polynukleotidsekvenser |
| WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| US6939994B1 (en) | 2004-09-23 | 2005-09-06 | Catalytic Distillation Technologies | Process for the production of bisphenol-A |
| JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 |
| BRPI0718677A2 (pt) * | 2006-11-03 | 2013-11-26 | Irm Llc | Compostos e composições como inibidores de quinases proteicas |
| EP4230747A3 (en) | 2008-03-28 | 2023-11-15 | Pacific Biosciences Of California, Inc. | Compositions and methods for nucleic acid sequencing |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CA2782299A1 (en) | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| EP2580378A4 (en) | 2010-06-08 | 2014-01-01 | Nugen Technologies Inc | MULTIPLEX SEQUENCING METHODS AND COMPOSITION |
| TWI552751B (zh) | 2011-06-20 | 2016-10-11 | Ｈ 朗德貝克公司 | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法 |
| WO2013025939A2 (en) * | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| KR20130077390A (ko) | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| HUE037689T2 (hu) | 2012-09-14 | 2018-09-28 | Hoffmann La Roche | Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra |
| CA2904393A1 (en) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| KR20190095355A (ko) * | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
-
2017
- 2017-12-15 KR KR1020197020051A patent/KR20190095355A/ko not_active Ceased
- 2017-12-15 WO PCT/US2017/066839 patent/WO2018112420A1/en not_active Ceased
- 2017-12-15 CA CA3047125A patent/CA3047125A1/en active Pending
- 2017-12-15 RU RU2019121922A patent/RU2019121922A/ru unknown
- 2017-12-15 BR BR112019012263-0A patent/BR112019012263A2/pt not_active Application Discontinuation
- 2017-12-15 CN CN201780086355.9A patent/CN110291084A/zh active Pending
- 2017-12-15 AU AU2017378487A patent/AU2017378487B2/en not_active Ceased
- 2017-12-15 US US16/468,948 patent/US11136297B2/en active Active
- 2017-12-15 JP JP2019532079A patent/JP7191828B2/ja active Active
- 2017-12-15 EP EP17881029.7A patent/EP3555077B1/en active Active
- 2017-12-15 MX MX2019007030A patent/MX392368B/es unknown
-
2019
- 2019-06-11 IL IL267247A patent/IL267247B/en unknown
-
2023
- 2023-03-31 US US18/194,410 patent/US12077507B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514254A5 (https=) | ||
| RU2019121922A (ru) | Композиции и способы лечения рака | |
| JP2020521741A5 (https=) | ||
| ES2881228T3 (es) | Sulfonilureas y compuestos relacionados y uso de los mismos | |
| JP2018519357A5 (https=) | ||
| RU2019105534A (ru) | Модуляторы хемокинового рецептора и их применение | |
| JP2019510004A (ja) | メニン−ｍｌｌの置換された阻害剤及びその使用方法 | |
| JP2020521742A5 (https=) | ||
| JP2019508426A (ja) | メニン−ｍｌｌの架橋された二環式阻害剤及びその使用方法 | |
| Al-Hadiya et al. | Imatinib mesylate | |
| JP2019508426A5 (https=) | ||
| EP3461821A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP2016520131A5 (https=) | ||
| JP2005508300A5 (https=) | ||
| JP2017528498A5 (https=) | ||
| Jiang et al. | A2B adenosine receptor antagonists with picomolar potency | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| JP2008504304A5 (https=) | ||
| JP2019507793A5 (https=) | ||
| TW201444850A (zh) | 巨環ｌｒｒｋ２激酶抑制劑 | |
| BRPI0516516A (pt) | derivados de 5-arilamino-1h-piridina-2-ona 3,6-substituìda e compostos relacionados como inibidores de poli(adp-ribose) polimerase (parp) no tratamento de dano ou doença dos tecidos causad(o)a por necrose ou apoptose | |
| GEAP202416543A (en) | 4-phenyl-2-(1h-1,2,3-triazol-4-yl)piperidin-4-ol derivatives as inhibitors of apol1 and methods of using same | |
| UY29454A1 (es) | Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos | |
| IL257951A (en) | Innovative derivatives of piperazine and piperidine, methods for their synthesis and uses as inhibitors of vdac oligomerization, apoptosis and disruption of mitochondrial activity | |
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications |